Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24343452 | 0.88 | DHFR (0.54) | DHFR | |
| Talotrexin SCHEMBL29376907 | 0.84 | DHFR (0.79) | DHFR | |
| Talotrexin SCHEMBL1060264 | 0.84 | DHFR (0.79) | DHFR | |
| Talotrexin SCHEMBL30947427 | 0.84 | DHFR (0.79) | DHFR | |
| Talotrexin SCHEMBL1060263 | 0.84 | DHFR (0.79) | DHFR | |
| Talotrexin SCHEMBL31476904 | 0.84 | DHFR (0.79) | DHFR | |
| Talotrexin SCHEMBL29420103 | 0.84 | DHFR (0.78) | DHFR | |
| SCHEMBL30947423 | 0.82 | DHFR (0.54) | DHFR | |
| SCHEMBL4223731 | 0.81 | DHFR (0.58) | DHFR | |
| SCHEMBL4223738 | 0.81 | DHFR (0.58) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466111-B2 | Cyclopenta{G}quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia | BTG INTERNATIONAL LIMITED (GB) | 2013-06-18 | — | — | US | disclosed |
| EP-2293807-B1 | CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INT LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110190211-A1 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INTERNATIONAL LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| WO-2009115776-A1 | CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INTERNATIONAL LIMITED (GB) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190211-A1 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | ARGLU1, MCL1, GLUL | DHFR 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.